SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

SAWYER TOMI K

(Last)

(First)

(Middle)

C/O ARIAD PHARMACEUTICALS, INC.

26 LANDSDOWNE STREET

(Street)

CAMBRIDGE

02139

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/30/2003

3. Issuer Name and Ticker or Trading Symbol
ARIAD PHARMACEUTICALS INC [ ARIA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Drug Discovery

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	10,420	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock Options	12/09/1998⁽¹⁾	12/09/2007	Common Stock	20,000	$4.875	D
Common Stock Options	02/02/1999⁽²⁾	02/02/2008	Common Stock	2,500	$4.313	D
Common Stock Options	09/10/1999⁽³⁾	09/10/2008	Common Stock	20,000	$2.688	D
Common Stock Options	04/05/2000⁽⁴⁾	04/05/2009	Common Stock	15,000	$1.34	D
Common Stock Options	10/04/1999⁽⁵⁾	10/04/2009	Common Stock	7,000	$0.75	D
Common Stock Options	06/07/2002⁽⁶⁾	06/07/2011	Common Stock	50,000	$5.65	D
Common Stock Options	06/18/2003⁽⁷⁾	06/18/2012	Common Stock	40,000	$4.19	D
Common Stock Options	08/15/2004⁽⁸⁾	08/15/2013	Common Stock	30,000	$3.9	D
Common Stock Options	09/23/2004⁽⁹⁾	09/23/2013	Common Stock	10,000	$6.39	D

Explanation of Responses:

1. Exercisable 25% per year, commencing on 12/9/1998.

2. Exercisable 25% per year, commencing on 2/2/1999.

3. Exercisable 25% per year, commencing on 9/10/1999.

4. Exercisable 25% per year, commencing on 4/5/2000.

5. Exercisable 25% on date of grant and 25% per quarter for the subsequent three quarters.

6. Exercisable 25% per year, commencing on 06/7/2002.

7. Exercisable 25% per year, commencing on 6/18/2003.

8. Options vest 100% at the one-year anniversary of the date of the award.

9. Exercisable 25% per year, commencing on 9/23/2004.

	Edward M. Fitzgerald Attorney-in-Fact	10/03/2003
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.